Please check your internet connection and try again.
# Hepa-Merz (L-Ornithine L-Aspartate / LOLA)
## Overview
Hepa-Merz is a stable salt of two endogenous amino acids, L-ornithine and L-aspartate. It functions by stimulating the urea cycle in the liver and promoting glutamine synthesis in the muscle, thereby facilitating ammonia detoxification in patients with hyperammonemia due to chronic liver disease.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy (HE).
* Management of hyperammonemia associated with acute or chronic liver diseases (e.g., cirrhosis, fatty liver).
## Adult Dosing
* **Oral (Granules):** 1 sachet (3g) 3 times daily, taken after meals dissolved in a glass of water, juice, or tea.
* **Intravenous (Severe cases/HE):** Up to 4 ampoules (40g) daily. For overt HE, infuse 20g (2 ampoules) initially diluted in 500mL of compatible IV fluid over 4–6 hours. Do not exceed an infusion rate of 5g/hour.
* *Note: Dosing varies significantly by local clinical protocols and severity of encephalopathy.*
## Pediatric Dosing
Safety and efficacy in children have not been rigorously established. Use is generally **not recommended** unless directed by a pediatric hepatologist under strict supervision. No standardized weight-based dosing exists in common international guidelines.
## Dose Adjustments
* **Renal Impairment:** Patients with severe renal insufficiency (creatinine > 3 mg/dL) require extreme caution as LOLA metabolites are excreted renally.
* **Hepatic Impairment:** No dose reduction required; however, monitor ammonia levels.
## Contraindications
* Hypersensitivity to L-ornithine or L-aspartate.
* Severe renal impairment (renal failure).
* Presence of severe metabolic acidosis (lactate/pyruvate metabolism disorders).
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, stomach pain, flatulence.
* **Rare:** Limb pain, pruritus, allergic skin reactions.
* **General:** High IV infusion rates may cause nausea/vomiting.
## Key Drug Interactions
There are no major, well-documented medicinal drug-drug interactions for LOLA. However, avoid mixing with other medications in the same IV bag to prevent compatibility issues.
## Monitoring
* Monitor serum ammonia levels to assess efficacy.
* Monitor renal function (BUN/Creatinine) in patients with baseline impairment.
* Observe mental status (West Haven Criteria) for neuro-psychiatric improvement.
## Clinical Pearls
* **Administration:** Oral granules must be dissolved in fluid. IV administration requires close monitoring to ensure the infusion rate does not exceed 5g per hour to prevent secondary side effects.
* **Not a monotherapy:** LOLA is an adjunct to standard HE management, which primarily relies on lactulose and/or rifaximin to reduce enteric ammonia production.
* **Stability:** If using IV, use only clear solutions immediately after opening.
***
**Disclaimer:** This information is for educational purposes only. Clinical guidelines and local prescribing protocols vary globally. Always verify specific dosing, safety data, and contraindications by consulting the official product monograph or your hospital's clinical pharmacy department before prescribing or administering any medication.
